APA (7th ed.) Citation

WY, J., J, M., HM, K., Y, A., G, B., E, J., . . . F, R. (2025). Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer, 131(1), e35662. https://doi.org/10.1002/cncr.35662

Chicago Style (17th ed.) Citation

WY, Jen, et al. "Long-term Follow-up of a Phase 2 Study of All-trans Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Acute Promyelocytic Leukemia." Cancer 131, no. 1 (2025): e35662. https://doi.org/10.1002/cncr.35662.

MLA (9th ed.) Citation

WY, Jen, et al. "Long-term Follow-up of a Phase 2 Study of All-trans Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Acute Promyelocytic Leukemia." Cancer, vol. 131, no. 1, 2025, p. e35662, https://doi.org/10.1002/cncr.35662.